Evidence map›Paper›PMID 25936991›Full record

ArticleMolecular medicine reports2015

Mitogen-activated protein kinase mediates mevalonate-stimulated human mesangial cell proliferation.

Xiaoshuang Zhou, Chen Wang, Jihua Tian, Yanhong Wang, Yafeng Li, Zhaoyong Hu, Rongshan Li

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xiaoshuang ZhouDepartment of Nephrology, Provincial People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Shanxi Kidney Disease Institute, Taiyuan, Shanxi 030001, P.R. China.
Chen WangDepartment of Pathology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Jihua TianDepartment of Microbiology and Immunology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Yanhong WangDepartment of Microbiology and Immunology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Yafeng LiDepartment of Nephrology, Provincial People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Shanxi Kidney Disease Institute, Taiyuan, Shanxi 030001, P.R. China.
Zhaoyong HuDepartment of Nephrology, Baylor College of Medicine, Houston, TX 77030, USA.
Rongshan LiDepartment of Nephrology, Provincial People's Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Shanxi Kidney Disease Institute, Taiyuan, Shanxi 030001, P.R. China.
Shanxi Medical University · CNBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metabolic products of intracellular mevalonate (MVA) are important for the growth of eukaryotic cells. These products include cholesterol and several non-sterol isoprenoids. It has been reported that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ameliorate glomerular injury in several experimental models of progressive glomerular disease by inhibiting the production of MVA and its metabolites. However, the mechanisms by which MVA stimulates the growth of human mesangial cells (HMCs) remain to be elucidated. To investigate the role of MVA in HMC proliferation, apoptosis, cell cycle and accumulation of extracellular matrix (ECM), the effects of MVA on HMCs at different durations and at various doses were evaluated. To examine the mechanisms of the effects of MVA on HMCs, the cells were treated with MVA, with or without PD98059, an extracellular signal-regulated kinase (ERK) inhibitor, SP600125, c-Jun NH2-teminal kinase (JNK) inhibitor, or SB203580, a P38 mitogen-activated protein kinase (MAPK) inhibitor. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction assay was used to measure the proliferation of the HMCs, a flow cytometric assay was used to assess the proliferative index, and an ELISA was performed to determine the expression of transforming growth factor-β1 (TGF-β1), Type IV and Type I collagen (Col-IV and Col-I). The expression of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), phosphorylated (p)-ERK1/2, p-JNK and p-p38 were also examined using western blot analysis. MVA significantly stimulated HMC proliferation and markedly increased the secretion of TGF-β1 and expression levels of Col-IV and Col-I. In addition, treatment with MVA significantly upregulated the expression of Bcl-2 and suppressed the expression of Bax in the HMCs. These responses were partially inhibited by the addition of inhibitors of ERK or JNK, however, they were not inhibited by the p38 MAPK inhibitor. These results demonstrated that MVA promoted HMC proliferation and ECM protein expression, which were associated with an increase in the expression of TGF-β1 and the inhibition of apoptosis. These effects were mediated, at least in part, by the JNK and ERK pathways.

Indexed as

AnthracenesApoptosisbcl-2-Associated X ProteinCell CycleCell LineCell ProliferationCollagen Type ICollagen Type IVDose-Response Relationship, DrugExtracellular MatrixFlavonoidsGene Expression RegulationHumansImidazolesJNK Mitogen-Activated Protein KinasesMesangial Cells2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneAnthracenesBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanCollagen Type ICollagen Type IVFlavonoidsImidazolesJNK Mitogen-Activated Protein KinasesMAPK1 protein, humanMevalonic AcidMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2pyrazolanthronePyridinesSB 203580Transforming Growth Factor beta1

Identifiers

PMID25936991
PMCPMC4464046
OpenAlexW1947771247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.